ArticleClinical pharmacology and therapeutics2022

Coproporphyrin I as an Endogenous Biomarker to Detect Reduced OATP1B Activity and Shift in Elimination Route in Chronic Kidney Disease.

Hiroyuki Takita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.